Wolverine Trading’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-13,900
Closed -$62K 6772
2021
Q4
$62K Sell
13,900
-2,900
-17% -$13.8K ﹤0.01% 5261
2021
Q3
$83K Buy
16,800
+4,800
+40% +$26.5K ﹤0.01% 5869
2021
Q2
$82K Buy
12,000
+300
+3% +$2.42K ﹤0.01% 5490
2021
Q1
$80K Sell
11,700
-10,300
-47% -$74.2K ﹤0.01% 5517
2020
Q4
$136K Buy
22,000
+800
+4% +$4.71K ﹤0.01% 4387
2020
Q3
$116K Buy
+21,200
New +$105K ﹤0.01% 4087
2020
Q1
Sell
-21,600
Closed -$88K 5506
2019
Q4
$88K Buy
+21,600
New +$74.9K ﹤0.01% 4321
2019
Q2
Sell
-17,100
Closed -$92K 5311
2019
Q1
$92K Sell
17,100
-9,600
-36% -$62K ﹤0.01% 4171
2018
Q4
$138K Buy
+26,700
New +$203K ﹤0.01% 3863
2018
Q3
Sell
-13,500
Closed -$176K 6141
2018
Q2
$176K Hold
13,500
﹤0.01% 4464
2018
Q1
$176K Buy
+13,500
New +$201K ﹤0.01% 4464
2017
Q4
Sell
-11,800
Closed -$296K 5667
2017
Q3
$296K Sell
11,800
-3,600
-23% -$83.8K ﹤0.01% 3274
2017
Q2
$392K Buy
+15,400
New +$340K ﹤0.01% 2691

Other funds holding PRTK

Wolverine Trading's PRTK Position: Q1 2022 in Review

Wolverine Trading sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2022, closing a stake of 14,044 shares — an estimated $62K sold.

Wolverine Trading first reported a position in PRTK in Q2 2017 and held it in 10 quarters. The position peaked at $411K in Q3 2017. 100 funds tracked by Wall St. Rank hold PRTK as of Q1 2022.

  • Wolverine Trading reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Wolverine Trading sold 14,044 Paratek Pharmaceuticals, Inc. shares in Q1 2022, an estimated $62K.
  • Wolverine Trading first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 10 quarters.
  • Wolverine Trading's Paratek Pharmaceuticals, Inc. position peaked at $411K in Q3 2017.
  • 100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2022.

Based on Wolverine Trading's 13F filing for Q1 2022, filed 16 May 2022.